Answers are grounded in this paper and cite their sources.
Clinical review reveals broad antitumor efficacy and manageable toxicities of cisplatin across solid malignancies, highlighting strategies to improve its therapeutic index.
Cis-diamminedichloroplatinum (II) (DDP) leads the series of platinum coordination complexes, a new class of cytotoxic agents. The antitumor and toxic effects of this drug are discussed. It has displayed encouraging results in testicular tumors. The drug's therapeutic effectiveness has also been recognized in a variety of other solid tumors, particularly ovarian, bladder, and head and neck malignancies. Gastrointestinal, renal, audiologic, and relatively minor hematologic toxicities may be encountered, but promising methods have been developed to increase the therapeutic index of DDP.
No takes yet. Share an insight, caveat, or question.
Marcel Rozencweig (1977) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: